Breaking News

Vernalis, Servier Reach Oncology Research Milestones

August 4, 2014

Triggers €750K payment to Vernalis

Vernalis and Servier have achieved two milestones in their oncology discovery collaborations, triggering a payment of €750K to Vernalis.

The companies initiated their first collaboration in May 2007 utilizing Vernalis' fragment and structure-based drug discovery platform on several oncology targets, one of which is Bcl-2. Vernalis receives fees, development milestones, and royalties on potential sales. Financial terms were not disclosed.

Ian Garland, chief executive officer of Vernalis, said, "We are delighted to achieve these milestones, recognizing our very successful partnership with Servier and we look forward to further success from this relationship."

Jean Pierre Abastado, head of the Center for Therapeutic Innovation in Oncology at Servier, said, "Small molecules tailored against specific targets can have very high therapeutic potential. These new successes with Vernalis demonstrate the ability of this partnership to identify and characterize promising compounds which further extend Servier portfolio to treat cancer patients."

Related Contract Manufacturing:

  • CROs and Today’s  R&D Landscape

    CROs and Today’s R&D Landscape

    Kristin Brooks, Associate Editor, Contract Pharma||November 9, 2016
    John Lewis of ACRO discusses opportunities, challenges, and the future CRO

  • The Human Parts of Mouse Models

    The Human Parts of Mouse Models

    Julia Schueler, Head of in vivo Operations, Oncotest, a Charles River company ||October 11, 2016
    The PDX model system has come back into focus

  • Choosing Oral Formulations for First-in-man Clinical Trials

    Choosing Oral Formulations for First-in-man Clinical Trials

    Jon Sutch, Senior Manager of Formulation Development, Patheon||October 11, 2016
    Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems